Articles

According to Start-Up Nation Central (SNC), AI represents about 30% of Israel’s start-ups and attracts nearly half of total company funding.

Adv. and Patent Attorney Ehud Hausman, Head of the Hitech Practice, sheds light on patent protection policies in companies integrating generative AI technologies into their products and where Israel stands in comparison to the rest of the world.

Will a flawed R&D agreement for developing innovative herbicides jeopardize the success of a subsequent patent application? In the Bionome matter, the court in England was called upon to resolve a dispute between parties who engaged in a joint research and development project and later disagreed over patent ownership. Dr. John Russell Clearwater invented an […]

Further to the previous report in respect of the case of Diana Zohar v. Meta and adidas1,2, the Supreme Court recently rejected the appeal filed by Diana Zohar and upheld the ruling of the Tel Aviv District Court, which determined that Zohar employed sophisticated methods to conceal the sale of counterfeit goods, including using hidden […]

In an article for “The Marker” newspaper, Dima explains how patents can serve as a source of technological and business intelligence. He highlights how integrating patents with additional data sources can provide strategic insights and help identify opportunities.

Recognition of a Biological Substance as a “New Substance” Despite the Absence of Differences in the Primary and Secondary Structure of the Protein Compared to a Previously Registered Substance. For example, in the matter of Bayer,[8] a request for PTE was denied based on the finding that the amino acid sequence of the API in Kovaltry® […]

In a Nutshell In Unipharm v. Sanofi,[1] the Supreme Court accepted Unipharm’s claim for the restitution of profits derived by Sanofi in consequence of filing a patent application for a polymorph of an active ingredient of a drug that was protected by an earlier patent. In June 2024, the Supreme Court issued a ruling in a similar […]

A new regulatory scheme for pharmaceuticals was established in Israel. The scheme establishes a new regulatory pathway of temporary approvals for the importation and supply of pharmaceuticals during the time of the pendency of the marketing authorization applications. It also grants the HMOs the power to prioritize and affect the decision of which pharmaceuticals will […]

In December 2023, Israel’s Ministry of Health (“MoH”) published substantial revisions to the guidelines regulating policy and procedure for the registration and use of biosimilar pharmaceuticals in Israel (Procedure No. 127). The new guidelines ease requirements for registration and use of biosimilars in Israel. While the full effect of these revisions on the Israeli biopharmaceutical […]